NCT05116189 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05116189
Title	Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme Corp.
Indications	ovary epithelial cancer fallopian tube carcinoma peritoneal carcinoma
Therapies	Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| IRL \| GBR \| FRA \| FIN \| DNK \| DEU \| CAN \| BRA \| BEL \| AUS

No variant requirements are available.